|
|
Upfront Briefing
The marquee print came out of China: Innovent's IBI343 cleared Phase 3 and became the first CLDN18.2 ADC into a regulatory queue — a clean datapoint for the China-partnered ADC trade, landing the same week Washington's new BINSA bill went after exactly those licensing economics.
Otsuka leaned on fresh one-year Voyxact data to keep its IgAN case alive, and FDA leadership stayed in the tape — voucher pushback plus an acting commissioner already heading for the exit. Healthcare topped the board (XLV +3.1%), but that was a chips-to-defensives rotation off Broadcom, not biotech conviction.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,584.3 |
0.4% |
10.6% |
| Nasdaq 100 |
30,407.8 |
(0.5%) |
20.6% |
| Russell 2000 |
2,935.3 |
1.4% |
17.0% |
| Healthcare (XLV) |
152.1 |
3.1% |
(2.2%) |
| Biotech (XBI) |
133.4 |
2.8% |
9.8% |
| Nasdaq Biotech (NBI) |
5,941.7 |
2.3% |
4.1% |
| Clinical Trials (BBC) |
43.0 |
2.5% |
11.4% |
|
- Healthcare led the tape — XLV +3.1%, XBI +2.8%, NBI +2.3% — but the move was a rotation out of semiconductors into large-cap defensives (UnitedHealth ~+5%, J&J ~+4.6%), not biotech-specific catalysts.
- The rotation was triggered by Broadcom's ~12.6% drop on a soft AI-chip outlook (AMD ~(3.6%), Micron ~(7.7%)), which left the Nasdaq slightly red (~(0.1%)) even as the Dow jumped ~1.7% to a record and the S&P 500 added 0.4%.
- Market data: U.S. cash close Thursday, 4 June 2026.
The Big 3
|
1
|
Innovent's CLDN18.2 ADC hits Phase 3, first to regulatory review
|
- IBI343 (arcotatug tavatecan), which Takeda licensed for $1.2B ex-China last year, met its progression-free survival endpoint at a first interim analysis in a 464-patient China/Japan trial in heavily pretreated CLDN18.2-positive gastric and GEJ cancer; China's NMPA accepted it for priority review — the first CLDN18.2-directed ADC to enter regulatory review.
- Why it matters: Read it as directional, not done — the win came at a first interim look (n=464), OS is still pending, and the actual numbers are held back for a conference. But it's the first CLDN18.2 ADC into a regulatory queue, and it hands the exatecan-payload approach a real proof point over Astellas' approved Vyloy antibody and the chasing pack: AstraZeneca, Moderna, and a Merck that already gave back its Kelun asset. The catch sits in Washington — Takeda's $1.2B ex-China economics are precisely what BINSA and a widening COINS Act want under review (see Everything Else). Own the read-through, respect the policy tail.
- Source: Fierce Biotech
- More: PR
|
|
2
|
Otsuka cites new Voyxact IgAN data in approval bid
|
- Voyxact, a monoclonal antibody for IgAN, showed one-year data suggesting slower kidney function loss, though coverage said the benefit came in lighter than expected as Otsuka pushes for full approval.
- Why it matters: The whole call hangs on the one-year eGFR slope — strong enough to carry a full approval, or just enough to keep the FDA conversation going? Coverage already reads the benefit as lighter than hoped, and IgAN is crowding fast, with the APRIL/BAFF and FcRn names all circling. A modest signal probably still clears approval, but with a thinner commercial story, softer peak-sales math, and less firepower for Otsuka's next kidney-franchise move. Net: good enough to win a label, not enough to own the category.
-
Source:
STAT
-
More:
Otsuka
|
| 3 | FDA faces pressure over rare disease meeting, vouchers |
- Acting FDA Commissioner Kyle Diamantas — who said he does not want the job permanently — pledged to prevent political interference at a rare disease meeting, while industry and patient groups urged the agency to pause the commissioner's voucher program.
- Why it matters: This is a process-risk story, not a data story — but for rare-disease names, process is the data. If the voucher program gets paused or politicized, anyone leaning on accelerated-review optics takes a sentiment hit and multiple compression with nothing changing in the clinic. An acting commissioner already signaling he won't stay only widens the discount rate on names whose value rests on FDA predictability. Trade it as a sector-wide overhang on the accelerated-approval cohort, not a single-ticker move.
- Source: STAT
- More: BioCentury
|
Everything Else that broke
- Lundbeck's anti-PACAP mAb bocunebart hit its Phase IIb migraine endpoint versus placebo. — PR
- Reps. Moolenaar and Dingell introduced the Biotech Investment National Security Act (BINSA), which would subject U.S.–China biopharma licensing deals and JVs to COINS Act review and names Pfizer and BMS, while RA Capital's Peter Kolchinsky publicly pushed back. — Fierce Biotech
- The EC cleared LOJUXTA for children aged 5 and older with HoFH. — PR
- Mabwell won NMPA IND clearance for 9MW5211 in inflammatory bowel disease. — PR
- Hikma said a unanimous Supreme Court ruling effectively ends Amarin's patent dispute. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Gilead and Lakefront closed Ouro Medicines’ acquisition, adding gamgertamig for autoimmune development. — PR
VC / Private Financings
- Ona Therapeutics raised an $86.6M Series B to advance its ADC pipeline in breast cancer; investors include Columbus Venture Partners, Mérieux Equity Partners, COFIDES, Korys, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI, FundPlus NV and Ysios Capital. — Fierce Biotech
IPOs / Follow-Ons
- NRx closed a $22.3M common stock offering led by B Group Capital, joined by Columbia Threadneedle, Corbets, Venture 76 and Mossrock. — PR
Academic Corner - A phase I study in three patients showed preliminary safety and efficacy for AAV8-mediated LDL receptor gene therapy in homozygous familial hypercholesterolemia. — Nature Medicine
- Nature Biotech argued the first FDA-approved PROTAC validates targeted protein degradation as a therapeutic approach. — Nature Biotech
|
That's the tape. China keeps shipping the data, Washington keeps drafting the brakes — position for both sides. See you Monday. BioBucks Team.
|
|
|
